Kuldeep Kumar

1.1k total citations
10 papers, 209 citations indexed

About

Kuldeep Kumar is a scholar working on Infectious Diseases, Immunology and Neurology. According to data from OpenAlex, Kuldeep Kumar has authored 10 papers receiving a total of 209 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Infectious Diseases, 3 papers in Immunology and 2 papers in Neurology. Recurrent topics in Kuldeep Kumar's work include SARS-CoV-2 and COVID-19 Research (2 papers), Biosimilars and Bioanalytical Methods (2 papers) and COVID-19 Clinical Research Studies (2 papers). Kuldeep Kumar is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (2 papers), Biosimilars and Bioanalytical Methods (2 papers) and COVID-19 Clinical Research Studies (2 papers). Kuldeep Kumar collaborates with scholars based in India, Malaysia and United States. Kuldeep Kumar's co-authors include Sushila Kataria, Pooja Sharma, Pawan Singh, Deepak Govil, Narendra S. Choudhary, Vikas Agarwal, Shashikala Sangle, Manoj Goel, Dhruva Chaudhry and Arvinder S. Soin and has published in prestigious journals such as The Lancet Respiratory Medicine, Expert Opinion on Investigational Drugs and Expert Opinion on Biological Therapy.

In The Last Decade

Kuldeep Kumar

7 papers receiving 205 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kuldeep Kumar India	3	150	104	34	27	21	10	209
Xixin Yan China	6	88 0.6×	45 0.4×	12 0.4×	26 1.0×	39 1.9×	11	204
Georgina Russell United Kingdom	6	81 0.5×	85 0.8×	21 0.6×	27 1.0×	37 1.8×	19	199
Maheswari Kulandhasamy India	8	218 1.5×	99 1.0×	6 0.2×	49 1.8×	12 0.6×	17	296
Xinghua Tan China	8	116 0.8×	29 0.3×	38 1.1×	31 1.1×	3 0.1×	22	233
Jinjin Liu China	9	330 2.2×	113 1.1×	6 0.2×	29 1.1×	15 0.7×	33	395
Qin Mao China	2	211 1.4×	70 0.7×	4 0.1×	49 1.8×	8 0.4×	6	297
Kamal Abu Jabal Israel	5	246 1.6×	103 1.0×	4 0.1×	17 0.6×	8 0.4×	16	337
Guoyu Tan China	3	186 1.2×	86 0.8×	2 0.1×	12 0.4×	14 0.7×	4	218
Francesc Puchades Gimeno Spain	7	154 1.0×	24 0.2×	6 0.2×	15 0.6×	34 1.6×	15	252
Khalil Ansarin Iran	7	137 0.9×	46 0.4×	3 0.1×	42 1.6×	36 1.7×	12	241

Countries citing papers authored by Kuldeep Kumar

Since Specialization

Citations

This map shows the geographic impact of Kuldeep Kumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kuldeep Kumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kuldeep Kumar more than expected).

Fields of papers citing papers by Kuldeep Kumar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kuldeep Kumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kuldeep Kumar. The network helps show where Kuldeep Kumar may publish in the future.

Co-authorship network of co-authors of Kuldeep Kumar

This figure shows the co-authorship network connecting the top 25 collaborators of Kuldeep Kumar. A scholar is included among the top collaborators of Kuldeep Kumar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kuldeep Kumar. Kuldeep Kumar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Szepietowski, Jacek C., Adam Reich, Steven R. Feldman, et al.. (2025). Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study. Expert Opinion on Biological Therapy. 25(8). 913–924.

Ackroyd, J F, et al.. (2025). Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon’s ustekinumab (Bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: results from the Study to Test pharmacokinetic BioEquivalence of BiosimiLar ustekinumab to SteLARa (STELLAR-1). Expert Opinion on Investigational Drugs. 34(4). 349–357. 2 indexed citations

Dhir, Varun, Seehui Chiu, Padmanabha Shenoy, et al.. (2024). Conventional Synthetic Disease-modifying Drugs Remain the Mainstay of Therapy for Rheumatoid Arthritis in India. Journal of the Association of Physicians of India. 72(12). 30–33. 1 indexed citations

Chandrasekaran, Gokul, et al.. (2024). Analysis of Post-Traumatic Stress Disorder (PTSD) Using Electroencephalography. 1–6.

Kumar, Kuldeep, et al.. (2024). Performance Improvement of Lithium-ion Battery for Battery EVs. 1–6. 2 indexed citations

Kumar, Kuldeep, et al.. (2024). Intelligent Automation in Long Vehicles through LDR Sensor Technology for Accident Prevention. 1–6.

Kumar, Kuldeep, et al.. (2023). Ultrasonic Sensor Based Automatic Power Saving- System. 18. 1–6. 2 indexed citations

Soin, Arvinder S., Kuldeep Kumar, Narendra S. Choudhary, et al.. (2021). Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. The Lancet Respiratory Medicine. 9(5). 511–521. 148 indexed citations

Kataria, Sushila, Manish Kumar Singh, Rakesh Rana, et al.. (2021). A pilot clinical study of an add-on Ayurvedic formulation containing Tinospora cordifolia and Piper longum in mild to moderate COVID-19. Journal of Ayurveda and Integrative Medicine. 13(2). 100454–100454. 18 indexed citations

10.

Puthiyedath, Rammanohar, Sushila Kataria, Unnikrishnan Payyappallimana, et al.. (2020). Ayurvedic clinical profile of COVID-19 – A preliminary report. Journal of Ayurveda and Integrative Medicine. 13(1). 100326–100326. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact